MD lowered the risk of all-cause, cardiovascular and CAD/cerebrovascular mortality CVD patients, net of statins. In the same population, statins reduced CVD death risk only in combination with MD. Low-grade inflammation, rather than lipids, is likely to be on the pathway of the interaction between MD and statins towards mortality risk.
There are multiple links in the WP article to the original studies.
“When we see something that surprises us and flies in the face of what is understood, it requires another look — maybe a different cohort, larger numbers, longer follow-up,”
Surprised? As long as we continue to focus on pharmaceuticals as the answer, no one should be surprised.